Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142935 | 0.91 | PDE4B (0.63) | PDE4BLMNAPDE4DPDE4APDE4C | |
| SCHEMBL7798507 | 0.87 | NPC1 (0.48) | PDE4BLMNAPDE4DPDE4APDE4C | |
| SCHEMBL6657114 | 0.86 | PDE4B (0.56) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL143198 | 0.86 | PDE4B (0.56) | PDE4BLMNAPDE4DPDE4APDE4C | |
| SCHEMBL6654207 | 0.84 | PDE4A (0.51) | PDE4BPDE4DPDE4APDE4CKMT2A | |
| SCHEMBL6654125 | 0.84 | PDE4B (0.63) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL9099996 | 0.82 | PDE4B (0.64) | PDE4BLMNAPDE4DPDE4APDE4C | |
| SCHEMBL6677128 | 0.81 | PDE4B (0.56) | PDE4BLMNAPDE4DPDE4APDE4C | |
| SCHEMBL6654325 | 0.80 | PDE4B (0.61) | PDE4BLMNAPDE4DPDE4APDE4C | |
| SCHEMBL6654240 | 0.80 | PDE4B (0.61) | PDE4BLMNAPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1435958-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GmbH (DE) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003032993-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GMBH (DE) | 2003-04-24 | — | — | WO | disclosed |
| US-6531473-B2 | Phosphodiesterase inhibitor; antiinflammatory agents | MERCK PATENT GMBH (DE) | 2003-03-11 | — | — | US | disclosed |
| US-20020111356-A1 | Arylalkylpyridazinones | MERCK KGAA (DE) | 2002-08-15 | — | — | US | disclosed |
| US-6399611-B1 | 2-(4-ETHOXYCARBONYLAMINOBENZYL)-6-(3,4 -DIMETHOXYPHENYL)-2,3,4, 5-TETRAHYDROPYRIDAZIN-3-ONE OR ALTERNATELY BENZYL SUBSTITUTED COMPOUNDS; PHOSPHODIESTERASE IV AND TUMOUR NECROSIS FACTOR INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-06-04 | — | — | US | disclosed |
| EP-0738715-A2 | Arylalkyl-pyridazinones | MERCK PATENT GmbH (DE) | 1996-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | PDE4A, PDE3A, PDE3B | PDE4B 4/4885LMNA 2603/4885PDE4D 12/4885 |
| US-20020111356-A1 | Arylalkylpyridazinones | PDE4A, PDE5A, PDE2A | PDE4B 8/4885LMNA 4187/4885PDE4D 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.